CD8A and neoplasm: In fact, lesions with defective expression of HLA class I molecules may retain evidence for the development of adaptive immunity (High-ICR) and also for CD8+ T-cell infiltration, but down-modulation of MHC class I molecules on tumor cells prevents recognition of HLA/neoantigen complexes by T cells, thus suppressing the possibility of genetic immunoediting (therefore, the lesions are identified as Non-GIE).